Abstract
We studied the effects of recombinant human granulocyte colony-stimulating factor (G-CSF) on hematopoietic recovery and clinical outcome in patients undergoing allogeneic peripheral blood stem cell (PBSC) transplantation. Fifty-six patients with hematological malignancies who underwent allogeneic PBSC transplantation between 1995 and 1998 were entered into this study. Twenty-eight patients who received daily G-CSF from day +1 after allogeneic PBSC transplantation until the absolute neutrophil count (ANC) reached >0.5 × 109/l for 3 consecutive days were compared with 28 patients (control group) who did not receive G-CSF in a non-randomized manner. The study group and the control group were comparable with respect to baseline patient and transplantation characteristics. Median times to ANC of >0.5 × 109/l and 1 × 109/l with or without G-CSF were 12 days (range 8–21), 13 days (10–32) (P = 0.04) and 13 days (9–21), 15 days (11–44) (P = 0.02), respectively. Median times to reach a platelet count of >20 × 109/l with and without G-CSF were 11 days (0–20) and 13 days (9–26), respectively (P = 0.03). The incidence of febrile episodes was significantly lower with G-CSF, 75% vs 100% (P = 0.008). Patients receiving G-CSF had less grade III–IV mucositis than those who did not receive G-CSF (P = 0.01). There was also no increase in the incidence and severity of acute GVHD in patients using G-CSF (P = 0.22). Although the number of relapsing patients was greater in the G-CSF group (seven vs three patients), this was not statistically significant (P = 0.24). Disease-free and overall survival rates did not differ between the two groups (P = 0.58 and 0.53, respectively). The administration of G-CSF after allogeneic PBSC transplantation provided faster neutrophil and platelet engraftment associated with less severe mucositis and less febrile episodes. Bone Marrow Transplantation (2001) 27, 499–505.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Masaoka T, Takaku F, Kato S et al. Recombinant human granulocyte–macrophage colony-stimulating factor in allogeneic bone marrow transplantation Exp Hematol 1985 17: 1047–1450
Linch D, Scarffe H, Proctor S et al. Randomised vehicle controlled dose finding study of glycosylated recombinant human granulocyte-colony stimulating factor after bone marrow transplantation Bone Marrow Transplant 1993 11: 307–310
Nemunaitis J, Buckner CD, Appelbaum FR et al. Phase I/II trial of recombinant granulocyte–macrophage colony stimulating factor following allogeneic bone marrow transplantation Blood 1991 77: 2065–2071
Powles R, Smith C, Milan S et al. Human recombinant GM-CSF in allogeneic bone marrow transplant for leukemia: double blind placebo controlled trial Lancet 1990 336: 1417–1420
DeWitte T, Gratwohl A, Van Der LN et al. Recombinant human granulocyte-colony stimulating factor accelerates neutrophil and monocyte recovery after allogeneic T-cell-depleted bone marrow transplantation Blood 1992 79: 1359–1365
Nemunaitis J, Rosenfeld C, Ash R et al. Phase III double blind trial of rhGM-CSF following bone marrow transplant Blood 1993 82: 1128a
Schriber RJ, Chao NJ, Long GD et al. Granulocyte colony-stimulating factor after allogeneic bone marrow transplantation Blood 1994 84: 1680–1684
Linch JD, Milligan DW, Winfield DA et al. G-CSF after peripheral blood stem cell transplantation in lymphoma patients significantly accelerated neutrophil recovery and shortened time in hospital: results of a randomised BNLI trial Br J Haematol 1997 99: 933–938
Dunlop DJ, Fitasimons EJ, McMurray A et al. Filgrastim fails to improve hematopoietic reconstitution following myeloablative chemotherapy and peripheral blood stem cell rescue Br J Cancer 1994 70: 943–945
Spitzer G, Adkins DR, Spencer V et al. Randomized study of growth factors post-peripheral-stem-cell transplant: neutrophil recovery is improved with modest clinical benefit J Clin Oncol 1994 12: 661–670
Schimazaki C, Oku N, Uchiyama H et al. Hematopoietic recovery after peripheral blood progenitor cell transplantation Bone Marrow Transplant 1994 13: 271–275
Gratwohl A, Passweg J, Baldomero H, Hermans J . Blood and bone marrow transplantation activity in Europe Bone Marrow Transplant 1998 22: 227–240
Majolino I, Saglino G, Scime R et al. High incidence of chronic GVHD after primary allogeneic peripheral blood stem cell transplantation Bone Marrow Transplant 1996 17: 555–560
Üstün C, Arslan Ö, Beksac M et al. A retrospective comparison of allogeneic peripheral blood stem cell and bone marrow transplantation results from a single center: a focus on the incidence of graft versus host disease and relapse Biol Blood Marrow Transplant 1999 5: 28–35
Körbling M, Przepiorka D, Huh YO et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts Blood 1995 85: 1659–1665
Körbling M, Fliedner TM . The evaluation of clinical peripheral blood stem cell transplantation Bone Marrow Transplant 1996 17: (Suppl. 2) 4–11
Russell JA, Brown C, Bowen T et al. Allogeneic blood cell transplantation for hematologic malignancy: preliminary comparison of outcome with bone marrow transplantation Bone Marrow Transplant 1996 17: 703–708
Rosenfeld C, Collins R, Pineiro L et al. Allogeneic blood cell transplantation without posttransplant colony-stimulating factors in patients with hematopoietic neoplasm: a phase II study J Clin Oncol 1996 4: 1314–1319
Pavletic ZS, Michael R, Bishop R et al. Hematopoietic recovery after allogeneic blood stem-cell transplantation compared with bone marrow transplantation in patients with hematologic malignancies J Clin Oncol 1997 15: 1608–1616
Bensinger WI, Clift R, Martin P et al. Allogeneic peripheral blood stem cell transplantation with advanced hematologic malignancies: a retrospective comparison with marrow transplantation Blood 1996 88: 2794–2800
Przepiorka D, Weisdorf D, Martin P et al. Consensus conference on acute GVHD grading Bone Marrow Transplant 1995 15: 825–828
Nemunaitis J, Anasetti C, Storb R et al. Phase I/II trial of recombinant human granulocyte–macrophage colony-stimulating factor in patients undergoing allogeneic bone marrow transplantation from unrelated donors Blood 1992 79: 2572–2577
Przepiorka D, Smith T, Folloder J et al. A controlled trial of filgrastim for acceleration of neutrophil recovery after allogeneic blood stem cell transplantation Blood 1998 92: (Suppl. 1) 523a
Urbano-Ispizua A, Garcia-Conde J, Brunet S et al. for Spanish Group of Allogeneic PBSC Transplantation High incidence of chronic graft versus host disease (GVHD) after allogeneic blood progenitor cell transplantation (allo-PBSCT) from matched related donors Blood 1996 88: (Suppl. 1) 2455a
Ringden O, Remberger M, Runde V et al. Peripheral blood stem cell transplantation from unrelated donors: a comparison with marrow transplantation Blood 1999 94: 454–464
Karthaus M, Rosenthal C, Ganser A . Prophylaxis and treatment of chemo- and radiotherapy-induced oral mucositis – are there new strategies? Bone Marrow Transplant 1999 24: 1095–1108
Bensinger W, Appelbaum F, Rowley S et al. Factors that influence collection and engraftment of autologous peripheral blood stem cells J Clin Oncol 1995 13: 2547–2555
Berger C, Bertz H, Schmoor C et al. Influence of recombinant human granulocyte colony-stimulating factor (filgastrim) on hematopoietic recovery and outcome following allogeneic bone marrow transplantation (BMT) from volunteer unrelated donors Bone Marrow Transplant 1999 23: 983–990
Gisselbrecht C, Prentice HG, Bacigalupo A et al. Placebo-controlled phase III trial of lenograstim in bone-marrow transplantation Lancet 1994 343: 696–700
Martin-Algarra S, Bishop MR, Tarantolo S et al. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis Exp Hematol 1995 23: 1503–1508
Nemunaitis J, Rosenfeld CS, Ash R et al. Phase III randomized, double-blind placebo-controlled rhGM-CSF following allogeneic bone marrow transplantation Bone Marrow Transplant 1995 15: 949–954
Gordon B, Spadinger A, Hodges E et al. Effect of granulocyte–macrophage colony stimulating factor on oral mucositis after hematopoietic stem cell transplantation J Clin Oncol 1994 12: 1917–1922
Azevedo WM, Aranha FJP, Gouvea JV et al. Allogeneic transplantation with blood stem cells mobilized by G-CSF for hematologic malignancies Bone Marrow Transplant 1995 16: 647–653
Schmitz N, Dreger P, Suttorp M et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by Filgrastim (G-CSF) Blood 1995 85: 1666–1672
Hagglund H, Ringden O, Remberger M et al. Faster neutrophil and platelet engraftment, but no differences in acute GVHD or survival, using peripheral blood stem cells from related and unrelated donor, compared to bone marrow Bone Marrow Transplant 1998 22: 131–136
Pan L, Delmonte J, Jalonen C, Ferrara J . Pretreatment of donor mice with granulocyte-colony stimulating factor polarizes T-lymphocytes towards type 2 cytokine production and reduced severity of experimental graft-versus-host disease Blood 1995 86: 4422–4429
Storek J, Gooley T, Siadak M et al. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus host disease Blood 1997 90: 4705–4709
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Özcan, M., Üstün, C., Akçağlayan, E. et al. Recombinant human granulocyte colony-stimulating factor (rh-G-CSF) may accelerate hematopoietic recovery after HLA-identical sibling allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 27, 499–505 (2001). https://doi.org/10.1038/sj.bmt.1702816
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1702816
Keywords
This article is cited by
-
Bacterial blood stream infections (BSIs), particularly post-engraftment BSIs, are associated with increased mortality after allogeneic hematopoietic cell transplantation
Bone Marrow Transplantation (2019)
-
Optimal use of G-CSF administration after hematopoietic SCT
Bone Marrow Transplantation (2009)
-
Graft-versus-host-disease and granulocyte colony-stimulating factor administration after allogeneic stem cell transplantation
Leukemia (2005)
-
The effect of hematopoietic growth factors on the risk of graft-vs-host disease after allogeneic hematopoietic stem cell transplantation: a meta-analysis
Bone Marrow Transplantation (2003)